Persistent psychosis and medical complications after a single ingestion of MDMA "ecstasy" - A case report and review of the literature

Psychiatry

Volumn 6, Issue 7, 2009, Pages 40-44

  Potash, Mordecai N ^a   Gordon, Kimberly A ^a   Conrad, Kristy L ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiomyopathy; Ecstacy; MDMA; Seizure disorder; Substance abuse

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; HALOPERIDOL; LORAZEPAM; OLANZAPINE; VALPROIC ACID;

ADULT; ARTICLE; BEHAVIOR DISORDER; CASE REPORT; CONGESTIVE CARDIOMYOPATHY; DRUG UTILIZATION; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; INTENSIVE CARE UNIT; MALE; METABOLIC ALKALOSIS; NEUROTOXICITY; PERSISTENT PSYCHOSIS; PSYCHOSIS; SEIZURE; SINUS BRADYCARDIA; SUBSTANCE ABUSE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 77649194402     PISSN: 15505952     EISSN: 15555194     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Van Kampen J, Katz M. Persistent psychosis after a single ingestion of Ecstasy. Psychosomatics. 2001;42(6):525-527.
2. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet. 1992;340:384-387.
3. Freudenmann RW, Oxler F, Bernschneider-Reif S. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006;101(9):1241-1245.
4. Bennett D. Dr. Ecstasy. Magazine Section. The New York Times. Sunday, January 30, 2005.
5. McDowell DM. The hallucinogens, marijuana, and club drugs. In: Glabbard GO (ed). Gabbard's Treatments of Psychiatric Disorders, Fourth Edition Edition. Washington, DC: American Psychiatric Publishing, Inc, 2007.
6. Mithoefer M. A test of MDMA-assisted psychotherapy in people with posttraumatic stress disorder. Sponsor: Multidisciplinary Association for Psychedelic Studies. Clinical Trial Identifier: NCT00090064. Accessed on 01/30/2009 at http://www.clinicaltrials.gov
7. Halpern JH. MDMA-assisted therapy in people with anxiety related to advanced stage cancer. Sponsor: Brigham and Women's Hospital. Clinical Trial Identifier: NCT00252174. Accessed on 01/30/2009 at http://www.clinicaltrials.gov
8. US Drug Enforcement Administration: MDMA (Ecstasy). Last updated August 2006. Accessed on 01/17/2009 at http://www.usdoj.gov/dea/concern/mdma.html.
9. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Survey Results on Drug Use, 1975-2007: Volume I, Secondary School Students. NIH Publication No. 08-6418A. 2008. Accessed on 01/17/09 at http://www.monitoringthefuture.org/pubs/monographs/vol1-2007.pdf
10. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Survey Results on Drug Use, 1975-2007: Volume II, College Students and Adults Ages 19-45. NIH Publication No. 08-6418B. 2008. Accessed on 01/17/09 at http://www.monitoringthefuture.org/pubs/monographs/vol2-2007.pdf
11. Vohlken BA, Layton, SM. Instrumental separation of 3,4- methylenedioxyamphetamine (MDA) from 1-(3,4-methylenedioxyphenyl)-2-propanol, a co-eluting compound. Microgram J. 2003;1(1-2):32-36.
12. National Institute on Drug Abuse: 2006 Research Report MDMA (Ecstasy) Abuse. NIH Publication No. 06-4728. Accessed on 01/17/09 at http://www. drugabuse.gov/researchreports/mdma/
13. Smith KM, Larive LL, Romanelli F. Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and g-hydroxybutyrate. Am J Health-System Pharmacol. 2002;59:1067-1075.
14. Gouzoulis E, Daumann J. Neurotoxicty of methylenedioxyamphetamines (MDMA; ecstasy) in humans: How strong is the evidence for persistent brain damage? Addiction. 2006;101(3):348-361.
15. Vecellio M, Schopper C, Modestin J. Neuropsychiatric consequences (atypical psychosis and complex-partial seizures) of ectasy use: possible evidence for toxicityvulnerability predictors and implications for preventative and clinical care. J Psychopharmacol 2003;17(3):342-345.
16. Thomasius R, Zapletalova P, Petersen K, et al. Mood, cognition, and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 2006;20(2):211-225.
17. Hurley RA, Reneman L, Taber KH. Ecstasy in the brain: a model for neuroimaging. J Neuropsychiatry Clin Neurosc. 2002;14(2):125-129.
18. McGuire P, Fahy T. Chronic paranoid psychosis after misuse of MDMA ("ecstasy"). Br Med J 1991;302:697.
19. Simmons AM. New Orleans awash in drugs, addicts more alone than ever. Nation Section. The Los Angeles Times. April 8, 2007:8. Accessed on 06/10/2009 at http://articles.latimes.com/2007/apr/08/nation/na-detox8.
20. Times-Picayune Staff Writers. Nagin to Aussie radio: New Orleans bouncing back. The Times-Picayune. Published Thursday, June 11, 2009 and accessed on 06/11/2009 at http://www.nola.com
21. Potash MN. The struggle for mental healthcare in New Orleans: one case at a time. Psychiatry (Edgemont). 2008;5(7):34-43.
22. Mental illness and the criminal justice system. June 2009. Psychiatric Services. 2009;60(6). Accessed on June 12, 2009 at http://psychservices. psychiatryonline.org/cgi/content/short/60/6/725
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Press, Inc., 2001.